Your browser doesn't support javascript.
loading
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
LaRocca, Nicholas G; Hudson, Lynn D; Rudick, Richard; Amtmann, Dagmar; Balcer, Laura; Benedict, Ralph; Bermel, Robert; Chang, Ih; Chiaravalloti, Nancy D; Chin, Peter; Cohen, Jeffrey A; Cutter, Gary R; Davis, Mat D; DeLuca, John; Feys, Peter; Francis, Gordon; Goldman, Myla D; Hartley, Emily; Kapoor, Raj; Lublin, Fred; Lundstrom, Gary; Matthews, Paul M; Mayo, Nancy; Meibach, Richard; Miller, Deborah M; Motl, Robert W; Mowry, Ellen M; Naismith, Rob; Neville, Jon; Panagoulias, Jennifer; Panzara, Michael; Phillips, Glenn; Robbins, Ann; Sidovar, Matthew F; Smith, Kathryn E; Sperling, Bjorn; Uitdehaag, Bernard Mj; Weaver, Jerry.
Afiliação
  • LaRocca NG; National Multiple Sclerosis Society, New York, NY, USA.
  • Hudson LD; Critical Path Institute, Tucson, AZ, USA.
  • Rudick R; Biogen, Cambridge, MA, USA.
  • Amtmann D; University of Washington, Seattle, WA, USA.
  • Balcer L; NYU Langone Medical Center, New York, NY, USA.
  • Benedict R; University at Buffalo, Buffalo, NY, USA.
  • Bermel R; Cleveland Clinic, Cleveland, OH, USA.
  • Chang I; Biogen, Cambridge, MA, USA.
  • Chiaravalloti ND; Kessler Foundation, West Orange, NJ, USA.
  • Chin P; Genentech, San Francisco, CA, USA.
  • Cohen JA; Cleveland Clinic, Cleveland, OH, USA.
  • Cutter GR; UAB School of Public Health, Birmingham, AL, USA.
  • Davis MD; Teva Pharmaceuticals, Green Valley, PA, USA.
  • DeLuca J; Kessler Foundation, West Orange, NJ, USA.
  • Feys P; Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
  • Francis G; Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • Goldman MD; University of Virginia, Charlottesville, VA, USA.
  • Hartley E; Critical Path Institute, Tucson, AZ, USA.
  • Kapoor R; University College London, London, UK.
  • Lublin F; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Lundstrom G; Critical Path Institute, Tucson, AZ, USA.
  • Matthews PM; Imperial College London, London, UK.
  • Mayo N; McGill University, Montreal, QC, Canada.
  • Meibach R; Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • Miller DM; Cleveland Clinic, Cleveland, OH, USA.
  • Motl RW; University of Alabama at Birmingham, Birmingham, AL, USA.
  • Mowry EM; Johns Hopkins University, Baltimore, MD, USA.
  • Naismith R; Washington University in St. Louis, St. Louis, MO, USA.
  • Neville J; Critical Path Institute, Tucson, AZ, USA.
  • Panagoulias J; Sanofi Genzyme, Cambridge, MA, USA.
  • Panzara M; Sanofi Genzyme, Cambridge, MA, USA.
  • Phillips G; Biogen, Cambridge, MA, USA.
  • Robbins A; Critical Path Institute, Tucson, AZ, USA.
  • Sidovar MF; Acorda Therapeutics, Inc., Ardsley, NY, USA; KES Business Consulting LLC, Lyme, CT, USA.
  • Smith KE; National Multiple Sclerosis Society, New York, NY, USA.
  • Sperling B; Biogen, Cambridge, MA, USA.
  • Uitdehaag BM; VU University Medical Center, Amsterdam, The Netherlands.
  • Weaver J; Novartis Pharmaceuticals, East Hanover, NJ, USA.
Mult Scler ; 24(11): 1469-1484, 2018 10.
Article em En | MEDLINE | ID: mdl-28799444
BACKGROUND: The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) was formed by the National MS Society to develop improved measures of multiple sclerosis (MS)-related disability. OBJECTIVES: (1) To assess the current literature and available data on functional performance outcome measures (PerfOs) and (2) to determine suitability of using PerfOs to quantify MS disability in MS clinical trials. METHODS: (1) Identify disability dimensions common in MS; (2) conduct a comprehensive literature review of measures for those dimensions; (3) develop an MS Clinical Data Interchange Standards Consortium (CDISC) data standard; (4) create a database of standardized, pooled clinical trial data; (5) analyze the pooled data to assess psychometric properties of candidate measures; and (6) work with regulatory agencies to use the measures as primary or secondary outcomes in MS clinical trials. CONCLUSION: Considerable data exist supporting measures of the functional domains ambulation, manual dexterity, vision, and cognition. A CDISC standard for MS ( http://www.cdisc.org/therapeutic#MS ) was published, allowing pooling of clinical trial data. MSOAC member organizations contributed clinical data from 16 trials, including 14,370 subjects. Data from placebo-arm subjects are available to qualified researchers. This integrated, standardized dataset is being analyzed to support qualification of disability endpoints by regulatory agencies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bases de Dados Factuais / Avaliação de Resultados em Cuidados de Saúde / Avaliação da Deficiência / Esclerose Múltipla Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bases de Dados Factuais / Avaliação de Resultados em Cuidados de Saúde / Avaliação da Deficiência / Esclerose Múltipla Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article